ST Germain D J Co. Inc. Sells 117 Shares of ResMed Inc. (NYSE:RMD)

ST Germain D J Co. Inc. trimmed its stake in ResMed Inc. (NYSE:RMD) by 0.1% in the fourth quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The institutional investor owned 93,049 shares of the medical equipment provider’s stock after selling 117 shares during the quarter. ST Germain D J Co. Inc. owned approximately 0.06% of ResMed worth $21,279,000 at the end of the most recent reporting period.

Several other institutional investors have also recently made changes to their positions in the stock. Marshall Wace LLP bought a new stake in shares of ResMed in the 2nd quarter valued at about $77,285,000. Geode Capital Management LLC raised its stake in ResMed by 10.9% in the third quarter. Geode Capital Management LLC now owns 3,858,814 shares of the medical equipment provider’s stock valued at $939,114,000 after buying an additional 380,383 shares during the period. Greenvale Capital LLP lifted its position in shares of ResMed by 61.1% in the second quarter. Greenvale Capital LLP now owns 725,000 shares of the medical equipment provider’s stock valued at $138,780,000 after buying an additional 275,000 shares during the last quarter. Caisse DE Depot ET Placement DU Quebec boosted its stake in shares of ResMed by 726.3% during the 3rd quarter. Caisse DE Depot ET Placement DU Quebec now owns 283,801 shares of the medical equipment provider’s stock worth $69,281,000 after acquiring an additional 249,454 shares during the period. Finally, Renaissance Technologies LLC acquired a new position in shares of ResMed during the 2nd quarter worth approximately $42,036,000. Institutional investors and hedge funds own 54.98% of the company’s stock.

Wall Street Analysts Forecast Growth

Several equities research analysts have issued reports on RMD shares. Stifel Nicolaus started coverage on ResMed in a report on Friday, December 13th. They set a “hold” rating and a $250.00 price target for the company. Needham & Company LLC restated a “hold” rating on shares of ResMed in a research note on Friday, October 25th. Bank of America upped their price target on shares of ResMed from $240.00 to $270.00 and gave the company a “buy” rating in a research note on Thursday, September 26th. Royal Bank of Canada boosted their price objective on ResMed from $224.00 to $232.00 and gave the stock a “sector perform” rating in a report on Friday, October 25th. Finally, Baird R W upgraded ResMed to a “strong-buy” rating in a research note on Tuesday, September 24th. One analyst has rated the stock with a sell rating, seven have issued a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the stock currently has an average rating of “Hold” and a consensus target price of $233.09.

Insiders Place Their Bets

In related news, Director Witte Jan De sold 796 shares of the stock in a transaction that occurred on Tuesday, November 12th. The shares were sold at an average price of $248.81, for a total value of $198,052.76. Following the completion of the transaction, the director now owns 6,723 shares of the company’s stock, valued at $1,672,749.63. This represents a 10.59 % decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Peter C. Farrell sold 2,000 shares of the business’s stock in a transaction on Wednesday, December 4th. The stock was sold at an average price of $245.65, for a total transaction of $491,300.00. Following the sale, the director now directly owns 81,218 shares in the company, valued at approximately $19,951,201.70. The trade was a 2.40 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 11,099 shares of company stock worth $2,719,385 over the last three months. Insiders own 0.71% of the company’s stock.

ResMed Price Performance

Shares of NYSE:RMD traded down $1.86 during trading on Friday, reaching $234.31. 278,653 shares of the company traded hands, compared to its average volume of 634,728. The firm has a market capitalization of $34.40 billion, a PE ratio of 31.03, a PEG ratio of 1.73 and a beta of 0.70. ResMed Inc. has a 52 week low of $168.29 and a 52 week high of $260.49. The company has a quick ratio of 1.91, a current ratio of 2.92 and a debt-to-equity ratio of 0.13. The company’s 50 day moving average is $240.05 and its two-hundred day moving average is $230.52.

ResMed (NYSE:RMD) last announced its quarterly earnings data on Thursday, October 24th. The medical equipment provider reported $2.20 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $2.03 by $0.17. The firm had revenue of $1.22 billion for the quarter, compared to the consensus estimate of $1.19 billion. ResMed had a net margin of 23.15% and a return on equity of 25.53%. The business’s revenue for the quarter was up 11.1% on a year-over-year basis. During the same period in the prior year, the company posted $1.64 earnings per share. As a group, sell-side analysts predict that ResMed Inc. will post 9.34 earnings per share for the current year.

ResMed Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Thursday, December 12th. Shareholders of record on Thursday, November 7th were given a dividend of $0.53 per share. The ex-dividend date of this dividend was Thursday, November 7th. This represents a $2.12 annualized dividend and a yield of 0.90%. ResMed’s dividend payout ratio is currently 28.08%.

ResMed Profile

ResMed Inc develops, manufactures, distributes, and markets medical devices and cloud-based software applications for the healthcare markets. The company operates in two segments, Sleep and Respiratory Care, and Software as a Service. It offers various products and solutions for a range of respiratory disorders, including ApneaLink Air, a portable diagnostic device that measures oximetry, respiratory effort, pulse, nasal flow, and snoring; and NightOwl, a portable, cloud-connected, and disposable diagnostic device that measures AHI based on derived peripheral arterial tone, actigraphy, and oximetry over several nights.